Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus
Pfizer shares rose 2.8% to $27.22 Friday after the FDA granted priority review for a Hympavzi label expansion, with a decision expected in Q2 2026. Trading volume reached 50.7 million shares. The TrumpRx.gov drug-discount rollout put renewed focus on pricing, with over 30 Pfizer drugs listed at launch.